Clinical Trials Directory

Trials / Unknown

UnknownNCT06140641

Effects of the Bifidobacterium Longum BL21 on BMI, Metabolic Indicators, and Gut Microbiota in Overweight/Obese Adults

Effects of Supplementing the Bifidobacterium Longum BL21 on BMI, Metabolic Indicators, and Gut Microbiota in Overweight/Obese Adults: a Randomized, Double-blind, Placebo-controlled Trial

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
72 (estimated)
Sponsor
Qilu Hospital of Shandong University · Academic / Other
Sex
All
Age
18 Years – 65 Years
Healthy volunteers
Not accepted

Summary

The goal of this study is to investigate the effects of Bifidobacterium longum subspecies BL21 on BMI, metabolic indicators, and changes in gut microenvironment microbiota in overweight/obese adults. The blood, urine, and feces samples of the subjects need to be collected at 0,4 and 8 week and promptly tested in the laboratory. During the intervention period, all groups of subjects were required to take the corresponding products daily and record adverse reactions.

Detailed description

The goal of this study is to investigate the effects of Bifidobacterium longum subspecies BL21 on BMI, metabolic indicators, and changes in gut microenvironment microbiota in overweight/obese adults. Randomized grouping was used to provide probiotic BL21 or placebo intervention. The total duration of the study is 8 weeks, including 8 weeks (1-8 weeks) of intervention expectations. The subjects were followed up at weeks 2 and 6, and sampled at weeks 0, 4, and 8. After the intervention during the follow-up period, blood, urine, and feces samples of the subjects need to be collected and promptly tested in the laboratory. During the intervention period, all groups of subjects were required to take the corresponding products daily and record adverse reactions.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTProbioticsBifidobacterium Longum BL21 or placebo for 8 weeks.

Timeline

Start date
2023-11-10
Primary completion
2024-07-30
Completion
2024-08-30
First posted
2023-11-20
Last updated
2023-11-20

Source: ClinicalTrials.gov record NCT06140641. Inclusion in this directory is not an endorsement.